Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLA-695 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PLA-695 | DRUG | - |
Inclusion Criteria: * Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years * RA disease onset after 16 years of age and has had the disease for at least 6 months * Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once w...
PLA-695 is an investigational small molecule drug that Pfizer, Inc. is developing for rheumatoid arthritis, an inflammatory joint condition. It is in Phase 1 clinical development and has not been approved by the FDA. Pfizer trades on the New York Stock Exchange under the ticker PFE.
PLA-695 is being studied for the treatment of rheumatoid arthritis, a chronic inflammatory disease that affects the joints. It is an investigational therapy in Phase 1 development and is not approved for any use. Its only recorded trial enrolled adults with rheumatoid arthritis.
Pfizer, Inc. is developing PLA-695. The company is listed on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 trial of PLA-695 in adults with rheumatoid arthritis, which was conducted in the United States and Canada.
PLA-695 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The study evaluated the pharmacokinetic interaction between PLA-695 and methotrexate in adults with rheumatoid arthritis. PLA-695 is investigational and has not received FDA approval.
PLA-695 has been studied in one completed Phase 1 trial, NCT00440492, titled a study to evaluate the pharmacokinetic interaction between PLA-695 and methotrexate in adults with rheumatoid arthritis. It was an uncontrolled trial in participants aged 18 years and older, conducted in the United States and Canada. No trials are currently active.